Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis.

Psychopharmacology - 1 Oct 2017

Suetani Rachel J, Siskind Dan, Reichhold Heidi, Kisely Steve

Abstract excerpt

Clozapine is the gold standard medication for treatment refractory schizophrenia, but unfortunately, its use is also associated with many adverse metabolic side effects. There may be a strong genetic component to the development of these adverse effects. We undertook a systematic review to examine the evidence for genetic variation being associated with secondary metabolic outcomes in patients with schizophrenia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents
Share to Clozapine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Sectional Studies

Share to Genetic Variation

Share to Genotype

Share to Metabolic Syndrome

Share to Schizophrenia

Source

Identifiers

PMID: 28879574
DOI: 10.1007/s00213-017-4728-0

Genes

LEP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variants impacting metabolic outcomes among people on clozapine: a systematic review and meta-analysis.PMID 28879574Read ↗

Genetic Epidemiological Pipeline Identifies Candidate Markers of Clozapine-Induced Metabolic Dysfunction Revealing Potential Avenues for Precision Clozapine PrescriptionSemantic proximity Read ↗

HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.Semantic proximity Read ↗

A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia.Semantic proximity Read ↗

Pharmacogenetic Study of Antipsychotic-Induced Lipid and BMI Changes in Chinese Schizophrenia Patients: A Genome-Wide Association StudySemantic proximity Read ↗

Rare variants in pharmacogenes influence clozapine metabolism in individuals with schizophrenia.Semantic proximity Read ↗

Pharmacogenetic study of antipsychotic–induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association StudySemantic proximity Read ↗

HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients With SchizophreniaSemantic proximity Read ↗

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.Semantic proximity Read ↗

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study.Semantic proximity Read ↗

Genetics of antipsychotic-induced weight gain: update and current perspectives.Semantic proximity Read ↗

Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype.Semantic proximity Read ↗

Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian BiobankSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.